WO2005063734A3 - Substituierte thiophene - Google Patents

Substituierte thiophene Download PDF

Info

Publication number
WO2005063734A3
WO2005063734A3 PCT/EP2004/014335 EP2004014335W WO2005063734A3 WO 2005063734 A3 WO2005063734 A3 WO 2005063734A3 EP 2004014335 W EP2004014335 W EP 2004014335W WO 2005063734 A3 WO2005063734 A3 WO 2005063734A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted thiophenes
prophylaxis
diseases
treatment
thiophenes
Prior art date
Application number
PCT/EP2004/014335
Other languages
English (en)
French (fr)
Other versions
WO2005063734A2 (de
Inventor
Kai Thede
Tobias Wunberg
Timothy Lowinger
Diana Koletzki
Andreas Urban
Judith Baumeister
Kerstin Henninger
Original Assignee
Aicuris Gmbh & Co Kg
Kai Thede
Tobias Wunberg
Timothy Lowinger
Diana Koletzki
Andreas Urban
Judith Baumeister
Kerstin Henninger
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg, Kai Thede, Tobias Wunberg, Timothy Lowinger, Diana Koletzki, Andreas Urban, Judith Baumeister, Kerstin Henninger filed Critical Aicuris Gmbh & Co Kg
Priority to JP2006544336A priority Critical patent/JP2007532481A/ja
Priority to CA002550428A priority patent/CA2550428A1/en
Priority to EP04803948A priority patent/EP1694665A2/de
Publication of WO2005063734A2 publication Critical patent/WO2005063734A2/de
Priority to US11/455,253 priority patent/US20070099929A1/en
Publication of WO2005063734A3 publication Critical patent/WO2005063734A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Erfindung betrifft substituierte Thiophene und Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, insbesondere zur Verwendung als antivirale Mittel, insbesondere gegen Hepatitis C Viren.
PCT/EP2004/014335 2003-12-19 2004-12-16 Substituierte thiophene WO2005063734A2 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2006544336A JP2007532481A (ja) 2003-12-19 2004-12-16 置換チオフェン
CA002550428A CA2550428A1 (en) 2003-12-19 2004-12-16 Substituted thiophenes
EP04803948A EP1694665A2 (de) 2003-12-19 2004-12-16 Substituierte thiophene
US11/455,253 US20070099929A1 (en) 2003-12-19 2006-06-16 Substituted thiophenes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10359791A DE10359791A1 (de) 2003-12-19 2003-12-19 Substituierte Thiophene
DE10359791.3 2003-12-19

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/455,253 Continuation US20070099929A1 (en) 2003-12-19 2006-06-16 Substituted thiophenes

Publications (2)

Publication Number Publication Date
WO2005063734A2 WO2005063734A2 (de) 2005-07-14
WO2005063734A3 true WO2005063734A3 (de) 2007-08-30

Family

ID=34683575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/014335 WO2005063734A2 (de) 2003-12-19 2004-12-16 Substituierte thiophene

Country Status (7)

Country Link
US (1) US20070099929A1 (de)
EP (1) EP1694665A2 (de)
JP (1) JP2007532481A (de)
CN (1) CN101094845A (de)
CA (1) CA2550428A1 (de)
DE (1) DE10359791A1 (de)
WO (1) WO2005063734A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
KR100900304B1 (ko) 2001-06-11 2009-06-02 바이로켐 파마 인코포레이티드 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체
ES2345438T3 (es) 2002-12-10 2010-09-23 Virochem Pharma Inc. Compuestos y metodos para el tratamiento o prevencion de infecciones por flavivirus.
DE102005028077A1 (de) * 2004-12-22 2006-07-13 Aicuris Gmbh & Co. Kg Alkinyl-substituierte Thiophene
CN101218224B (zh) 2005-05-13 2013-05-08 Viro化学制药公司 治疗或预防黄病毒感染的组合物和方法
JP2009501546A (ja) * 2005-07-18 2009-01-22 ノバルティス アーゲー Ｈｃｖ複製についての小動物モデル
GB0602046D0 (en) * 2006-02-01 2006-03-15 Smithkline Beecham Corp Compounds
WO2007147794A1 (en) * 2006-06-19 2007-12-27 Smithkline Beecham Corporation Furan derivatives and their use as antiviral agents
WO2008017688A1 (en) * 2006-08-11 2008-02-14 Smithkline Beecham Corporation 2-carboxy thiophene derivatives as anti-viral agents
WO2008043791A2 (en) * 2006-10-13 2008-04-17 Smithkline Beecham Corporation Thiophene derivatives for treating hepatitis c
JP5290186B2 (ja) 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
ATE524465T1 (de) * 2006-11-17 2011-09-15 Glaxosmithkline Llc 2-carboxy-thiophen-derivate als viruzide
CN101977915B (zh) 2008-02-04 2014-08-13 埃迪尼克斯医药公司 大环丝氨酸蛋白酶抑制剂
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
JP5685181B2 (ja) 2009-03-05 2015-03-18 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗作用を有するシクロヘキサン誘導体
WO2010118078A1 (en) 2009-04-08 2010-10-14 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
CN102471327A (zh) * 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
JP2013501068A (ja) 2009-08-05 2013-01-10 アイディニックス ファーマシューティカルズ インコーポレイテッド 大環状セリンプロテアーゼ阻害剤
WO2011031669A1 (en) 2009-09-09 2011-03-17 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
NZ600608A (en) 2009-12-18 2015-01-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
AP2012006413A0 (en) 2010-01-15 2012-08-31 Gilead Sciences Inc Inhibitors of flaviviridae viruses
PT2523950T (pt) * 2010-01-15 2017-06-01 Gilead Sciences Inc Inibidores dos vírus flaviridae
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
PT2734515E (pt) 2011-07-13 2016-03-11 Gilead Sciences Inc Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae
TW201329025A (zh) 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US8759544B2 (en) 2012-08-17 2014-06-24 Gilead Sciences, Inc. Synthesis of an antiviral compound
US8927741B2 (en) 2012-08-17 2015-01-06 Gilead Sciences, Inc. Synthesis of an antiviral compound
JP6192836B2 (ja) 2013-07-30 2017-09-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｒｏｒｃモジュレーターとしてのアザインドール化合物
US20160229866A1 (en) 2013-09-20 2016-08-11 Idenix Pharmaceuticals Inc. Hepatitis c virus inhibitors
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
WO2015134560A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Solid forms of a flaviviridae virus inhibitor compound and salts thereof
SG11202006723SA (en) 2018-02-08 2020-08-28 Enyo Pharma Non-fused thiophene derivatives and their uses
CN109111376B (zh) * 2018-09-18 2021-09-14 四川医立特生物医药有限公司 一种2,5-双脱氧链霉胺衍生物及其应用
CN109374806B (zh) * 2018-11-07 2020-11-10 南京明捷生物医药检测有限公司 一种测定原料药中3-氨基噻吩含量的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
EP1321463A1 (de) * 2001-12-21 2003-06-25 Shire Biochem Inc. Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100851A2 (en) * 2001-06-11 2002-12-19 Shire Biochem Inc. Thiophene derivatives as antiviral agents for flavivirus infection
EP1321463A1 (de) * 2001-12-21 2003-06-25 Shire Biochem Inc. Thiazolderivate und ihre Verwendung zur Behandlung oder Vorbeugung von Infektionen durch Flaviviren

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAN LAVAL ET AL: "Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 3, 9 February 2004 (2004-02-09), pages 793 - 796, XP002328928, ISSN: 0960-894X *
CHAN LAVAL ET AL: "Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: Tertiary amides.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 14, no. 3, 9 February 2004 (2004-02-09), pages 797 - 800, XP002328927, ISSN: 0960-894X *

Also Published As

Publication number Publication date
US20070099929A1 (en) 2007-05-03
WO2005063734A2 (de) 2005-07-14
EP1694665A2 (de) 2006-08-30
CA2550428A1 (en) 2005-07-14
DE10359791A1 (de) 2005-07-21
JP2007532481A (ja) 2007-11-15
CN101094845A (zh) 2007-12-26

Similar Documents

Publication Publication Date Title
WO2005063734A3 (de) Substituierte thiophene
NL300933I2 (nl) Letermovir
WO2006072347A3 (de) Alkinyl-substituierte thiophene
WO2006072348A3 (de) Alkinyl-substituierte thiophene
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2006032342A3 (de) Arzneimittel enthaltend carbonylverbindungen sowie deren verwendung
WO2004022537A3 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2008079159A3 (en) Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases
WO2006072458A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
MX2007003031A (es) Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias.
MX2007002470A (es) Fenilaminotiazoles sustituidos y su uso.
WO2006124861A3 (en) Benzofuran compounds
ATE453642T1 (de) Substituierte phenylaminopyrimidine
WO2004112687A3 (en) Antiviral acylguanidine compounds and methods
WO2004071382A3 (en) Substituted heterocycles
HK1093729A1 (en) Substituted quinolones
WO2004112718A3 (en) Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
WO2006023843A3 (en) Novel heterocycles
WO2006089664A3 (de) Heterocyclylamid-substituierte imidazole
TW200510449A (en) Acylated nonadepsipeptides
TW200621799A (en) Acylated nonadepsipeptides II
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2550428

Country of ref document: CA

Ref document number: 11455253

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006544336

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2004803948

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200480041879.9

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004803948

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11455253

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004803948

Country of ref document: EP